Exelixis Q2 FY26 GAAP net income rises 14.72% to $212.1 million; revenue increases 10.63% to $628.7 million
EXEL•Expenses and outlook
R&D expense climbed to $212 million; SG&A expense increased to $147.6 million on higher marketing activity.
Updated 2026 revenue outlook fell to $2.5 billion-$2.55 billion; R&D expense forecast narrowed to $825 million-$875 million.
Second-quarter results
Exelixis posted Q2 2026 revenue of $628.7 million, up 10.63% from a year earlier, driven by higher sales volume.
GAAP net income rose to $212.1 million, while GAAP diluted EPS increased to $0.82.
Pipeline and launch preparations
Management highlighted continued cabozantinib growth, and preparations for a potential zanzalintinib launch in metastatic CRC, with an FDA action date of Dec. 3, 2026.
